Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Deferasirox

Deferasirox

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Deferasirox

24 trials tracked of Deferasirox: 12 in phase 3 or 4 and 4 with published results. The most-cited published study has 91 citations.

24Trials tracked
12Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 6 Phase 3 6 Phase 2 12
  1. Phase 4 Pilot Study for Patients With Poor Response to Deferasirox Completed · 91 cited
  2. Phase 3 Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients Completed · 72 cited
  3. Phase 4 Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food Completed · 28 cited
  4. Phase 3 Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation Completed · 10 cited
  5. Phase 4 Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia Completed
  6. Phase 4 Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis Completed
Show 18 more trials
  1. Phase 4 Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients Completed
  2. Phase 4 Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) Completed
  3. Phase 3 An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload Completed
  4. Phase 3 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Completed
  5. Phase 3 Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda Completed
  6. Phase 3 Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study Completed
  7. Phase 2 Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients Completed
  8. Phase 2 Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients Completed
  9. Phase 2 Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis Completed
  10. Phase 2 Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study Completed
  11. Phase 2 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed
  12. Phase 2 A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload. Completed
  13. Phase 2 Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload Completed
  14. Phase 2 Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients Completed
  15. Phase 2 Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study Completed
  16. Phase 2 The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study Completed
  17. Phase 2 Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis Completed
  18. Phase 2 Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment Completed

Showing the 24 most-cited and recently-updated of 24 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.